Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 041b59)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio. This formulation is designed to optimize the synergistic delivery of the two cytotoxic agents to leukemia cells while minimizing systemic toxicity. It is primarily indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The liposomal delivery system allows for prolonged exposure in the bone marrow and preferential uptake by leukemia cells, which enhances the efficacy of the combination compared to the standard 7+3 regimen of the individual drugs.
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicindaunorubicin and cytarabine liposome
02
Targets
DNADNA polymerase familyPOLG (Mitochondrial DNA polymerase gamma)TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 041b59).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 041b59).